<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles D Pusey, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mårten Segelmark, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fernando C Fervenza, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 02, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1368947499">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anti-GBM disease is a small vessel vasculitis in which circulating antibodies are directed against an antigen intrinsic to the glomerular basement membrane (GBM) and alveolar basement membrane (ABM), resulting in rapidly progressive glomerulonephritis and/or alveolar hemorrhage [
         <a href="#rid1">
          1
         </a>
         ]. Goodpasture syndrome and Goodpasture disease are older terms often used synonymously to refer to anti-GBM antibody-mediated disease but also to the clinical constellation of glomerulonephritis and pulmonary hemorrhage, regardless of the underlying pathogenesis.
        </p>
        <p>
         The pathogenesis, clinical manifestations, and diagnosis of anti-GBM disease will be reviewed here. The treatment of this disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3085.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         The differential diagnosis of glomerular disease and the approach to the patient with suspected kidney disease are discussed in detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7188.html" rel="external">
          "Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3565045394">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anti-GBM disease is rare, estimated to occur in fewer than two cases per million population [
         <a href="#rid1">
          1
         </a>
         ]. A study from Ireland reported a national incidence of 1.64 per million population per year and identified both temporal and spatial clusters of cases, suggesting environmental triggers for disease onset [
         <a href="#rid2">
          2
         </a>
         ]; similar incidence estimates have been reported from New Zealand and the Netherlands [
         <a href="#rid3">
          3,4
         </a>
         ]. Anti-GBM disease has been recognized in other White individuals and Asian individuals [
         <a href="#rid3">
          3,5,6
         </a>
         ] but is thought to be rarer in African individuals [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Anti-GBM disease accounts for approximately 15 percent of all cases of crescentic glomerulonephritis in large biopsy series [
         <a href="#rid7">
          7
         </a>
         ]. However, it is a rare cause of end-stage kidney disease (ESKD), accounting for 0.8 percent of all ESKD patients in one study [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Larger series of anti-GBM disease patients have shown a bimodal age distribution, with peak incidences in the third decade and in the sixth to seventh decades [
         <a href="#rid9">
          9-12
         </a>
         ]. The disease also occurs among children [
         <a href="#rid13">
          13
         </a>
         ]. Younger patients (&lt;30 years) are more likely to present with pulmonary hemorrhage, and older patients (&gt;50 years) are more likely to present with isolated glomerulonephritis [
         <a href="#rid10">
          10,14
         </a>
         ]. There appears to be a slight male predominance in the younger age group and a female predominance in the older age group.
        </p>
        <p class="headingAnchor" id="H2325998465">
         <span class="h1">
          PATHOGENESIS
         </span>
        </p>
        <p class="headingAnchor" id="H300971652">
         <span class="h2">
          Antibody formation and specificity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anti-GBM disease is caused by circulating antibodies directed against an antigen intrinsic to the glomerular basement membrane (GBM). These antibodies have the following properties:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specificity
         </strong>
         – The principal target for the anti-GBM antibodies is the NC1 domain of the alpha-3 chain of type IV collagen (alpha-3(IV) chain), one of six genetically distinct gene products found in basement membrane collagen [
         <a href="#rid15">
          15,16
         </a>
         ]. Further evidence for the importance of the alpha-3(IV) chain comes from a report of a
         <em>
          COL4A3
         </em>
         variant in familial anti-GBM disease [
         <a href="#rid17">
          17
         </a>
         ]. There are two principal conformational epitopes localized to the globular NC1 domain of the alpha-3(IV) chain [
         <a href="#rid18">
          18-20
         </a>
         ]. Anti-GBM antibodies constitute up to 1 percent of the circulating immunoglobulin G (IgG) in these patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The general limitation of injury to the glomeruli and alveoli parallels the tissue distribution of the alpha-3(IV) chain. In comparison to the more widespread distribution of the alpha-1 and alpha-2 chains of type IV collagen, expression of the alpha-3 chain is highest in the glomerular and alveolar basement membranes (ABMs); lower in the renal tubular basement membranes (TBMs); detectable in the choroid plexus, testis, cochlea, and retina; and virtually absent in many other tissues, such as the small intestine, skin, and placenta [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Anti-GBM antibodies may also be directed against other alpha chains [
         <a href="#rid22">
          22
         </a>
         ]. Antibodies eluted from the kidneys of patients with Goodpasture disease were shown to bind most strongly to alpha-3(IV) NC, but the majority also recognized alpha-5(IV) and, to a lesser extent, alpha-4(IV). The kidney-bound antibodies recognized the EA and EB epitopes in alpha-3(IV) and the EA epitope in alpha-5(IV). They did not bind native cross-linked alpha-3, 4, 5 hexamers until they were dissociated [
         <a href="#rid23">
          23
         </a>
         ]. Exposure of cryptic epitopes occurs through disruption of sulfilimine cross-links in the NC1 domain, and this may be caused by autoantibodies directed against peroxidasin [
         <a href="#rid24">
          24
         </a>
         ]. Rarely, anti-GBM antibodies are directed exclusively against the alpha-4(IV) chain, and such antibodies will not be detected by assays that detect the alpha-3(IV) recombinant antigen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Isotype
         </strong>
         – Anti-GBM antibodies are usually IgG, with IgG1 and IgG3 subclasses predominant [
         <a href="#rid25">
          25,26
         </a>
         ]. Rare cases involving immunoglobulin A (IgA) and IgG4 antibodies have also been reported [
         <a href="#rid27">
          27-29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clonality
         </strong>
         – Anti-GBM antibodies are typically polyclonal (derived from multiple independent lymphocytes; having multiple epitope specificities), although rare cases of anti-GBM disease caused by monoclonal antibodies (derived from a single clone of lymphocytes; having a single, uniform epitope specificity) have been reported [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The production of these autoantibodies is short-lived and thought to be in response to an unknown inciting stimulus [
         <a href="#rid1">
          1
         </a>
         ]. The development of anti-GBM antibodies may precede the onset of clinical signs and symptoms by many months [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         The pathogenicity of anti-GBM antibodies has been demonstrated by passive transfer experiments in which antibodies obtained from the plasma or eluted from the glomeruli of patients with this disorder produced glomerulonephritis when infused into animals. The ability of these antibodies to bind rapidly and tightly to the GBM may underlie the typically fulminant nature of this disease [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         The variable pathogenicity of different anti-GBM antibodies is consistent with a report that antibodies against the alpha-3(IV) chain exist in normal individuals without evidence of kidney disease [
         <a href="#rid34">
          34
         </a>
         ]. In this report, the anti-GBM titers and avidity were substantially lower and of a different IgG subclass distribution than seen in patients with anti-GBM disease. As these autoantibodies could be found in all studied sera, they may represent natural autoantibodies, found without immunization in all mammals and important for opsonizing debris.
        </p>
        <p>
         Patients with and without alveolar hemorrhage appear to have similar autoantibodies against the alpha-3(IV) chain [
         <a href="#rid15">
          15
         </a>
         ]. The variable presence of pulmonary disease appears to reflect a general lack of access of the circulating anti-GBM antibodies to the ABM or to the cryptic nature of the antigen. Thus, patients with pulmonary involvement often have underlying pulmonary injury due to smoking or, less frequently, infection, cocaine inhalation, or hydrocarbon exposure [
         <a href="#rid35">
          35-37
         </a>
         ]. One report, however, described antibodies binding to laminin-521 in approximately one-third of patients with anti-GBM disease, particularly in those with pulmonary hemorrhage [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="local">
          'Environmental triggers'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H127907206">
         <span class="h2">
          Activation of complement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoantibodies binding to the GBM cause damage by activating the complement system, leading to neutrophil recruitment by C5a and cellular injury by the terminal membrane attack complex [
         <a href="#rid39">
          39
         </a>
         ]. Animal experiments indicate that both the classical and alternative pathways are involved, while evidence for the lectin pathway was not evident [
         <a href="#rid40">
          40
         </a>
         ]. An important role of complement factor C3 was also suggested by two clinical studies showing that intensive C3 staining and slightly reduced C3 levels in serum were associated with a worse prognosis [
         <a href="#rid41">
          41,42
         </a>
         ]. Similar results have been reported earlier using an assay for the circulating terminal membrane attack complex [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1487589377">
         <span class="h2">
          Autoreactive T cells
         </span>
         <span class="headingEndMark">
          —
         </span>
         Experimental models and clinical studies suggest that autoreactive T cells may contribute to the development of anti-GBM disease [
         <a href="#rid19">
          19,44-48
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T cells isolated from patients with this disorder, but not from controls, react against the alpha-3 chain of type IV collagen, the same molecule against which the anti-GBM antibodies are directed [
         <a href="#rid19">
          19,49
         </a>
         ]. Regulatory T cells (CD4+ CD25+) appear to play a role in regulation of the autoimmune response [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In experimental autoimmune glomerulonephritis, both Th1 and Th17 cells play a role in crescent formation [
         <a href="#rid50">
          50
         </a>
         ]. The administration of an anti-CD8 monoclonal antibody or an anti-CD154 antibody could prevent and/or treat experimental crescentic glomerulonephritis [
         <a href="#rid44">
          44,46
         </a>
         ]. Similarly, regulatory T cells (CD4+ CD25+), which counter the effects of autoreactive T cells, reduce the severity of glomerular lesions in murine anti-GBM glomerulonephritis [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A T cell epitope-inducing anti-GBM disease in experimental models has been characterized [
         <a href="#rid51">
          51,52
         </a>
         ]. Mucosal tolerance and protection from disease could be induced by nasal administration of a dominant epitope [
         <a href="#rid53">
          53
         </a>
         ]. Certain microbial peptides have similarities to this T cell epitope and elicit production of anti-GBM antibody and severe glomerulonephritis [
         <a href="#rid54">
          54,55
         </a>
         ]. Peptides complementary to the dominant peptide in alpha-3(IV) can also induce experimental glomerulonephritis via the idiotype/anti-idiotype network [
         <a href="#rid56">
          56
         </a>
         ]. Epitope spreading may explain immune responses to other regions of the alpha-3 chain and the alpha-4 chain [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These observations suggest that autoreactive T cells, in addition to enhancing B cell function and antibody production, may have a direct causative role in glomerular and alveolar injury. The presence of potentially autoreactive T cells in normal individuals has been demonstrated by a study showing primary T cell responses to peptides derived from the alpha-3(IV) chain [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3297236372">
         <span class="h2">
          Environmental triggers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anti-GBM disease is most often of unknown etiology, although it can occasionally be found with a temporal association with prior pulmonary and kidney injury  (
         <a class="graphic graphic_table graphicRef127108" href="/z/d/graphic/127108.html" rel="external">
          table 1
         </a>
         ). The association with infections may lead to clustering of cases, as was observed in North West London, United Kingdom, during the coronavirus disease 2019 (COVID-19) pandemic [
         <a href="#rid59">
          59,60
         </a>
         ] (see
         <a class="local">
          'Epidemiology'
         </a>
         above). Immune dysregulation, either inborn or acquired, also appears to predispose to anti-GBM antibody generation and anti-GBM disease. It seems logical that glomerular and alveolar damage causes the release of increased amounts of autoantigen. If natural antibodies normally are involved in the clearance of such debris, an increased release would trigger an increased production, which in cases of immune dysregulation could become uncontrolled.
        </p>
        <p>
         It is also possible that the associated injury results in ensuing damage and reveals an epitope that is normally hidden from the immune system [
         <a href="#rid59">
          59
         </a>
         ]. Another possibility of the pulmonary association is that damage to alveolar capillaries that occurs in these settings allows access of existing circulating anti-GBM antibodies to antigen in the ABM.
        </p>
        <p>
         Anti-GBM disease has been reported following treatment with the lymphocyte-depleting agent
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         [
         <a href="#rid61">
          61
         </a>
         ]. The loss of regulatory T cell subsets or abnormal immune cell reconstitution after lymphocyte depletion may contribute to the development of anti-GBM disease and other autoimmune disorders after exposure to this agent.
        </p>
        <p>
         Immune checkpoint inhibitor therapy has also been associated with rare cases of anti-GBM disease, including one case without detectable circulating anti-GBM antibodies [
         <a href="#rid62">
          62-65
         </a>
         ]. The mechanisms underlying this association remain unclear.
        </p>
        <p class="headingAnchor" id="H3282673463">
         <span class="h2">
          Genetic susceptibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rare cases of familial anti-GBM disease have been reported [
         <a href="#rid17">
          17,66-68
         </a>
         ], and there is increasing evidence that genetic factors affect the susceptibility to anti-GBM disease. Patients with HLA-DR15 and -DR4 appear to be at increased risk, while those with DR1 and DR7 are at lesser risk [
         <a href="#rid69">
          69
         </a>
         ], and the association with DR15 has been confirmed in Chinese [
         <a href="#rid70">
          70
         </a>
         ] and Japanese patients [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         The importance of genetic factors in determining the development of anti-GBM disease is supported by findings in rodent models. In mice immunized with alpha-3(IV) NC1, the emergence of crescentic glomerulonephritis and lung hemorrhage was restricted to mice with major histocompatability complex (MHC) haplotypes H-2s, b, or d [
         <a href="#rid72">
          72
         </a>
         ]. The nephritogenic response in H-2s maps more specifically to the Ab/Aa region. Organ inflammation was also associated with the emergence of an IL-12/Th1-like T cell phenotype, a finding consistent with a role for T cells as mentioned above. In rats with experimental anti-GBM glomerulonephritis, susceptibility was determined by copy number variation in the Fcgr3 gene [
         <a href="#rid73">
          73
         </a>
         ] and by expression of the AP-1 transcription factor JunD [
         <a href="#rid74">
          74
         </a>
         ]. Studies in congenic rats showed that both of these genetic loci have effects on susceptibility by modulating macrophage activity [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         More specific molecular analysis of DR beta chains has found that a particular six-amino-acid motif common to DRw15 and DR4 may confer disease susceptibility [
         <a href="#rid76">
          76
         </a>
         ]. This motif interacts with a short nephritogenic sequence of the alpha-3(IV) chain, which is in close vicinity of the EA epitope recognized by the anti-GBM autoantibodies [
         <a href="#rid77">
          77
         </a>
         ]. One experimental study suggests that when this epitope is presented by DR1 instead of DR15 the peptide exposes a different set of amino acid residue side-chains, and this promotes the development of tolerogenic CD4+ T regulatory cells specific for the alpha-3(IV) chain [
         <a href="#rid78">
          78
         </a>
         ]. The tolerogenic response promoted by DR1 seems to be dominant over the nephritogenic response induced by DR15. Using the same model, investigators were able to prevent and treat experimental anti-GBM disease by blocking the DR15 molecule with a peptide [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2022123984">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1491596137">
         <span class="h2">
          Overview of typical findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most (approximately 90 percent) patients with anti-GBM disease present with clinical features of rapidly progressive glomerulonephritis. Between 25 and 60 percent present with concomitant alveolar hemorrhage, and a small proportion of patients present with isolated pulmonary findings. (See
         <a class="medical medical_review" href="/z/d/html/3113.html" rel="external">
          "Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         Systemic complaints and signs, such as malaise, weight loss, fever, or arthralgia, are usually experienced only for a few weeks. The presence of such signs for a longer period suggests that the patient is double positive for anti-GBM and anti-myeloperoxidase (MPO-ANCA) and has features of concurrent vasculitis [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         Serum complement levels are typically within the normal range in patients with anti-GBM disease.
        </p>
        <p>
         Other variants of atypical anti-GBM disease have been reported. (See
         <a class="local">
          'Other variants'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2853444364">
         <span class="h2">
          Kidney manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presentation of anti-GBM disease is similar to that of other forms of rapidly progressive glomerulonephritis: relatively acute kidney injury with a urinalysis showing proteinuria (which is usually not in the nephrotic range) and a nephritic sediment characterized by dysmorphic red cells (including acanthocytes), white cells, and red cell and granular casts. Macroscopic hematuria is more common in anti-GBM disease compared with other forms of rapidly progressive glomerulonephritis.
        </p>
        <p>
         A relatively mild degree of kidney involvement may be more common than previously appreciated in patients with anti-GBM disease. A retrospective review from one center in Australia found that 5 of 14 patients (36 percent) with this disorder had hematuria and/or proteinuria but a normal creatinine clearance or serum concentration of creatinine [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1520662517">
         <span class="h2">
          Pulmonary manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary involvement, generally consisting of alveolar hemorrhage, affects 25 to 60 percent of patients. In rare cases, pulmonary disease predominates [
         <a href="#rid28">
          28,82
         </a>
         ]. Pulmonary manifestations include shortness of breath, cough, sometimes overt hemoptysis, pulmonary infiltrates on chest radiograph, and an increased carbon monoxide diffusing capacity (DLCO) due to the presence of hemoglobin in the alveoli. Iron deficiency anemia, possibly due to prolonged pulmonary bleeding, may be seen. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3677975383">
         <span class="h2">
          Other variants
         </span>
        </p>
        <p class="headingAnchor" id="H2343035553">
         <span class="h3">
          Double-positive anti-GBM and ANCA-associated disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute glomerulonephritis with or without pulmonary hemorrhage also may have granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Thus, the serum should be tested for antineutrophil cytoplasmic antibodies (ANCA), as well as anti-glomerular basement membrane (GBM) antibodies. Anti-GBM disease and systemic vasculitis not only have similar clinical manifestations, but between 10 and 50 percent of patients with anti-GBM disease also test positively for ANCA (usually anti-myeloperoxidase [MPO-ANCA]) at the time of diagnosis and may have signs of a systemic vasculitis or a marked systemic inflammatory response [
         <a href="#rid12">
          12,83-85
         </a>
         ]. (See
         <a class="local">
          'Serological testing'
         </a>
         below.)
        </p>
        <p>
         Low levels of ANCA may be detectable years before the production of anti-GBM antibodies and the onset of clinical symptoms. This was shown by an analysis of stored serum samples that had been obtained at the time of enlistment and every other year thereafter from 30 United States military personnel who subsequently developed anti-GBM disease [
         <a href="#rid32">
          32
         </a>
         ]. Patients who were diagnosed with anti-GBM disease and healthy controls were identified from the military database, and serum samples were obtained from the Department of Defense Serum Repository. Compared with matching controls, a greater number of patients with anti-GBM disease had anti-proteinase 3 (PR3-ANCA) and anti-myeloperoxidase (MPO-ANCA) levels detected in multiple serum samples that had been obtained in the years preceding the onset of disease (82 versus 14 percent in controls for PR3-ANCA, and 73 versus 27 percent in controls for MPO-ANCA). In all cases, ANCA were detected in earlier samples than anti-GBM antibodies, which were detected months, but not years, prior to the onset of clinical symptoms.
        </p>
        <p>
         The anti-GBM antibodies in patients who also have ANCA (double positive) have the same antigen specificity as those in patients with anti-GBM disease alone [
         <a href="#rid86">
          86
         </a>
         ]. However, a nation-wide Swedish and single-center Chinese study found that double-positive patients may have lower levels but a broader spectrum of anti-GBM antibodies compared with those with anti-GBM antibodies alone [
         <a href="#rid12">
          12,87
         </a>
         ]. In addition, ANCA-positive patients may develop a relapse of systemic vasculitis (see
         <a class="local">
          'Antibody formation and specificity'
         </a>
         above). Even if the patient was negative for ANCA on initial testing, ANCA serology should be repeated if there are signs of recurrent disease. (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p>
         The detection of ANCA is clinically relevant as these patients may be more likely to have treatable disease than those who have only anti-GBM antibodies. However, larger series suggest that the initial outcome is similar to those with anti-GBM disease alone [
         <a href="#rid4">
          4,84,85,88
         </a>
         ]. Longer-term management should be tailored to the vasculitis. (See
         <a class="medical medical_review" href="/z/d/html/3085.html" rel="external">
          "Anti-GBM (Goodpasture) disease: Treatment and prognosis", section on 'Whom to treat'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21673223">
         <span class="h3">
          Anti-GBM disease associated with membranous nephropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several cases of anti-GBM disease associated with membranous nephropathy (MN) have been described [
         <a href="#rid89">
          89-94
         </a>
         ]. The onset of anti-GBM disease may precede, coincide with, or follow the diagnosis of MN. In one series, patients with combined anti-GBM disease and MN (n = 8) had a lower serum creatinine level at diagnosis (524 versus 916 micromol/L [5.9 versus 10.4 mg/dL]), lower proportion with oliguria/anuria (0 versus 50 percent), and better kidney survival at one year (62 versus 13 percent) compared with patients with anti-GBM disease without MN (n = 30) [
         <a href="#rid91">
          91
         </a>
         ]. Although overall anti-GBM antibody levels were similar between the two groups, patients with combined anti-GBM disease and MN had lower antibody levels against the EB conformational epitope of alpha-3(IV) NC1. Serum antibodies against the phospholipase A2 receptor (PLA2R) were undetectable in patients with combined anti-GBM disease with MN.
        </p>
        <p>
         MN has also been associated with crescentic glomerulonephritis in patients with positive testing for ANCA [
         <a href="#rid92">
          92
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3051.html" rel="external">
          "Membranous nephropathy: Treatment and prognosis", section on 'Patients with crescentic GN'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3080237863">
         <span class="h3">
          Anti-GBM disease without detectable circulating anti-GBM antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         A rare variant of anti-GBM disease, described as "atypical anti-GBM nephritis", has been reported in a series of 20 patients who presented with hematuria, proteinuria, and mild kidney function impairment, without pulmonary hemorrhage [
         <a href="#rid95">
          95
         </a>
         ]. Kidney biopsy in these patients demonstrated bright, linear IgG deposition along the GBM but without features of crescentic glomerulonephritis. The evolution of the disorder was indolent and not rapidly progressive. Monoclonality was commonly observed. Anti-GBM antibodies were not detected with conventional assays or Western blot methods. One-year patient and kidney survival were 93 and 85 percent, respectively. These atypical cases accounted for approximately 12 percent of anti-GBM patients at the center.
        </p>
        <p>
         Similar clinical features were observed in another series of 60 patients from China [
         <a href="#rid96">
          96
         </a>
         ]. In this study, 5 percent had alveolar hemorrhage. All patients had linear IgG deposits on kidney biopsy; 42 percent showed crescent formation, and 8 percent had crescentic glomerulonephritis (crescents occupying &gt;50 percent of glomeruli). Over a mean of 36 months, 23 percent progressed to ESKD; deposition of C3 was associated with a worse kidney outcome.
        </p>
        <p>
         Several possible reasons may explain the discrepancy between positive linear staining for IgG in the kidney biopsy and negative commercial testing for circulating anti-GBM antibodies. First, circulating antibodies have a much shorter half-life than kidney-bound antibodies, and when antibody production ceases, there is a time interval during which antibodies are detectable in the kidney but not in the plasma. Secondly, commercial immunoassays for anti-GBM antibodies are based upon purified bovine or recombinant human alpha(IV) chains that contain the most common epitopes, but some patients react to other epitopes and even to other molecules. As an example, a case of anti-GBM disease has been described with circulating anti-laminin 521 antibodies but no circulating antibodies against alpha-3(IV) NC1 [
         <a href="#rid97">
          97
         </a>
         ]. There are reports of patients with negative testing by immunoassay who test positive for anti-GBM antibodies in other assays, such as indirect immunofluorescence using primate kidney sections, Western blot, and a biosensor system [
         <a href="#rid98">
          98,99
         </a>
         ]. Thirdly, some patients have anti-GBM antibodies with IgG4 subclass restriction, which may be less readily detected by some commercial assays. Interestingly, such patients with anti-GBM antibodies that are predominantly subclass IgG4 are frequently young female smokers with severe lung involvement [
         <a href="#rid28">
          28,100,101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3011857827">
         <span class="h3">
          Anti-GBM disease after transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         One interesting setting in which this disorder can occur is 5 to 10 percent of kidney transplants in patients with underlying Alport syndrome (hereditary nephritis) [
         <a href="#rid102">
          102
         </a>
         ]. These patients most commonly have an abnormality in the alpha-5 chain of type IV collagen, although alpha-3 and alpha-4 chain abnormalities may occur. This leads to defective organization of the alpha-5, -4 and -3 collagen chains in the basement membrane and altered Goodpasture antigen in the alpha-3 chain, so it is not recognized by anti-GBM antibodies. By comparison, the Goodpasture antigen is normal in the donor kidney, potentially initiating an immune response against this previously "unseen" antigen in the transplanted kidney [
         <a href="#rid102">
          102
         </a>
         ]. The alloantibody produced in X-linked Alport posttransplantation nephritis, however, recognizes a different epitope than the autoantibody in Goodpasture disease [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">
          "Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2404792439">
         <span class="h1">
          EVALUATION AND DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1729877186">
         <span class="h2">
          When to suspect anti-GBM disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of anti-GBM disease should be suspected in any patient presenting with clinical symptoms and/or signs concerning for acute or subacute nephritic syndrome (eg, hematuria, proteinuria, cellular casts, kidney function impairment), particularly if accompanied by rapid progression and/or pulmonary (alveolar) hemorrhage. Anti-GBM disease should also be suspected in patients presenting with alveolar hemorrhage alone since pulmonary disease may be the predominant presenting feature in rare cases. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults", section on 'Glomerulonephritis (hematuria with proteinuria, kidney function impairment, or other manifestations)'
         </a>
         .)
        </p>
        <p>
         In addition, the following clinical scenarios should raise suspicion for a less common variant of anti-GBM disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with features of systemic disease, such as malaise, weight loss, fever, or arthralgia, which suggest a concurrent vasculitis (see
         <a class="local">
          'Double-positive anti-GBM and ANCA-associated disease'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with the nephrotic syndrome who develop a rapid decline in kidney function (see
         <a class="local">
          'Anti-GBM disease associated with membranous nephropathy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with proteinuria, hematuria, or mild kidney function impairment who have linear IgG staining of the glomerular basement membrane (GBM) on kidney biopsy (see
         <a class="local">
          'Anti-GBM disease without detectable circulating anti-GBM antibodies'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney transplant recipients with underlying Alport syndrome (hereditary nephritis) who present with acute glomerulonephritis or graft failure (see
         <a class="local">
          'Anti-GBM disease after transplantation'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2126971329">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients suspected of having anti-GBM disease should undergo a diagnostic evaluation for possible causes of acute glomerulonephritis. In general, this evaluation consists of laboratory testing and, in many patients, a kidney biopsy to obtain a definitive diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults", section on 'Evaluation of glomerulonephritis'
         </a>
         .)
        </p>
        <p>
         The diagnosis of anti-GBM disease requires demonstration of anti-GBM antibodies either in the serum or the kidney. Kidney biopsy should be performed, unless there is a contraindication, because the accuracy of serologic assays is variable. In addition, kidney biopsy provides important information regarding the activity and chronicity of kidney involvement that may help guide therapy and excludes other possible causes of glomerulonephritis. (See
         <a class="local">
          'Kidney biopsy'
         </a>
         below and
         <a class="local">
          'Serological testing'
         </a>
         below.)
        </p>
        <p>
         Testing for antineutrophil cytoplasmic antibodies (ANCA), if not already performed as part of the initial evaluation of suspected glomerulonephritis, should be performed in all patients who are diagnosed with anti-GBM disease. The presence of both anti-GBM antibodies and ANCA supports a diagnosis of double-positive anti-GBM and ANCA-associated disease. (See
         <a class="local">
          'Serological testing'
         </a>
         below and
         <a class="local">
          'Double-positive anti-GBM and ANCA-associated disease'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1410727428">
         <span class="h3">
          Kidney biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A kidney biopsy should be performed without delay in all patients suspected of having anti-GBM disease, unless contraindicated. However, a kidney biopsy may be delayed in patients who require urgent treatment for alveolar hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/3067.html" rel="external">
          "The kidney biopsy", section on 'Contraindications'
         </a>
         .)
        </p>
        <p>
         Light microscopy usually shows crescentic glomerulonephritis (although milder cases do occur), whereas immunofluorescence microscopy demonstrates the virtually pathognomonic finding of linear deposition of IgG along the glomerular capillaries and occasionally the distal tubules  (
         <a class="graphic graphic_picture graphicRef68861 graphicRef76472 graphicRef63060 graphicRef57096 graphicRef78020" href="/z/d/graphic/68861.html" rel="external">
          picture 1A-E
         </a>
         ). In rare cases, the antibody may be IgA or immunoglobulin M (IgM) [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         In some cases, the tubular staining reflects distinct circulating anti-tubular basement membrane (TBM) antibodies. The observation that the associated tubulointerstitial disease (interstitial infiltrate and fibrosis, tubular atrophy) is more severe in patients with anti-TBM antibodies is consistent with these antibodies being pathogenetically important [
         <a href="#rid103">
          103
         </a>
         ]. However, alpha-3(IV) NC1 is present in a proportion of tubules (distal), so tubular deposits may reflect increased access of anti-GBM antibody to the TBM.
        </p>
        <p class="headingAnchor" id="H811367059">
         <span class="h3">
          Serological testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of anti-GBM disease can usually be established rapidly (particularly when kidney biopsy cannot be performed or will be delayed), either by serum assay for anti-GBM antibodies using a direct enzyme-linked immunoassay (ELISA) with purified or semi-purified antigens or by indirect immunofluorescence. Neither method is completely reliable; thus, a kidney biopsy to confirm the diagnosis is recommended unless contraindicated. (See
         <a class="local">
          'Kidney biopsy'
         </a>
         above.)
        </p>
        <p>
         As stated above, patients with suspected anti-GBM disease should also be tested for ANCA. (See
         <a class="local">
          'Double-positive anti-GBM and ANCA-associated disease'
         </a>
         above and
         <a class="local">
          'Establishing the diagnosis'
         </a>
         above.)
        </p>
        <p>
         The more common approach is the detection of anti-GBM antibodies in serum using a direct ELISA; the specificity of the antibody can be confirmed by Western blot [
         <a href="#rid104">
          104
         </a>
         ]. High antibody titers are usually found in those with rapidly progressive disease [
         <a href="#rid98">
          98,105
         </a>
         ]. The sensitivity varies depending upon the commercial kit used, ranging from 63 to nearly 100 percent [
         <a href="#rid105">
          105,106
         </a>
         ]. False-negative results may occur in those with low antibody titers [
         <a href="#rid98">
          98
         </a>
         ] and in some patients with Alport syndrome who develop posttransplant anti-GBM disease, with antibodies directed against the alpha-5(IV) chain [
         <a href="#rid107">
          107
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">
          "Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"
         </a>
         and
         <a class="local">
          'Anti-GBM disease without detectable circulating anti-GBM antibodies'
         </a>
         above.)
        </p>
        <p>
         False-positive results occasionally occur with commercial ELISA assays that do not use purified Goodpasture antigen [
         <a href="#rid104">
          104,105,108
         </a>
         ]. ELISA assays for the detection of anti-GBM antibodies that use native or recombinant human alpha-3(IV) antigen substrates are much more sensitive and specific, with reported sensitivity of 95 to 100 percent and specificity of 91 to 100 percent [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
         Indirect immunofluorescence is rarely performed and requires an experienced kidney pathologist. This test involves incubation of the patient's serum with normal human or primate kidney tissue. Fluorescein-labeled anti-human IgG is then added to see whether IgG deposition has occurred, and the results are compared with those obtained with normal serum. The test has a high false-negative rate, possibly as high as 40 percent. However, if performed appropriately and in the proper clinical setting (eg, severe acute glomerulonephritis), a positive test is probably diagnostic, although rigorous studies have not been performed.
        </p>
        <p>
         One case report provides an example in which commercial tests inaccurately suggested that a patient had anti-GBM antibodies, which was clarified using recombinant human alpha-3(IV) NC1 proteins [
         <a href="#rid108">
          108
         </a>
         ]. A patient with slowly progressive dyspnea, hematuria, and proteinuria had positive circulating anti-GBM antibodies as detected by standard testing and, on kidney biopsy, trace linear IgG deposits along the GBM. Repeat testing using recombinant human NC1 domains demonstrated that the patient had antibodies against alpha-2(IV) NC1 and not to the Goodpasture antigen alpha-3(IV) NC1. The positive commercial tests were probably detecting nonspecific cross-reactivity to alpha-3(IV) NC1.
        </p>
        <p class="headingAnchor" id="H2331327807">
         <span class="h3">
          Pulmonary studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary studies are not required to establish the diagnosis of anti-GBM disease; however, a chest radiograph is generally performed in patients who present with recent-onset hemoptysis or dyspnea. Findings on plain chest radiographs in patients with anti-GBM disease and alveolar hemorrhage are nonspecific and typically show new patchy or diffuse opacities. Further evaluation with high-resolution thoracic computed tomography (CT) scan, which characteristically shows ground glass or consolidative opacities in a diffuse and bilateral distribution, is necessary before pulmonary involvement can be ruled out (see
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Radiographic findings'
         </a>
         ). The gold standard to diagnose pulmonary hemorrhage when alternative reasons for pulmonary symptoms and signs are present is bronchoalveolar lavage [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4341.html" rel="external">
          "The diffuse alveolar hemorrhage syndromes", section on 'Bronchoalveolar lavage'
         </a>
         .)
        </p>
        <p>
         Pulmonary function testing is not routinely performed but may show an increased carbon monoxide diffusing capacity (DLCO), which is due to the presence of hemoglobin in the alveoli. However, in acute alveolar hemorrhage, the patient may not be sufficiently stable to perform this test. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1909341488">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of anti-GBM disease includes other causes of acute glomerulonephritis associated with pulmonary hemorrhage (ie, "pulmonary renal syndromes") and other kidney disorders in which linear IgG staining may be seen in the glomeruli on kidney biopsy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute glomerulonephritis with pulmonary hemorrhage ("pulmonary renal syndrome")
         </strong>
         – Pulmonary hemorrhage can also be seen with other acute nephritides due to pulmonary edema, or to lung involvement in antineutrophil cytoplasmic antibodies (ANCA)-positive and other forms of systemic vasculitis (such as IgA vasculitis [Henoch-Schönlein purpura] and mixed cryoglobulinemia syndrome) and systemic lupus erythematosus [
         <a href="#rid35">
          35
         </a>
         ]. In one report of 45 such patients, eight had anti-GBM disease, while 25 had a systemic vasculitis [
         <a href="#rid35">
          35
         </a>
         ]. Differentiating between these disorders upon the basis of clinical features alone can be difficult, and serologic testing and kidney biopsy are generally required to establish the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Establishing the diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6406.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">
          "Clinical manifestations of antiphospholipid syndrome", section on 'Pulmonary involvement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although they are not forms of acute glomerulonephritis, antiphospholipid antibody syndrome and pulmonary infection with concomitant acute kidney injury may also present in a similar manner to the pulmonary renal syndromes listed above [
         <a href="#rid109">
          109
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4678.html" rel="external">
          "Diagnosis of antiphospholipid syndrome", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Linear IgG staining on kidney biopsy
         </strong>
         – There are two other disorders in which linear IgG staining can be seen in the glomeruli: diabetic nephropathy and fibrillary glomerulonephritis. In the former and perhaps in the latter, the IgG is nonspecifically absorbed onto the highly permeable glomerular capillary wall and onto the fibrils, respectively. Staining is rarely as strong as with anti-GBM disease (see
         <a class="medical medical_review" href="/z/d/html/3115.html" rel="external">
          "Glomerular diseases due to nonamyloid fibrillar deposits"
         </a>
         ). In diabetic nephropathy, there is also linear deposition of albumin and other plasma proteins [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Diabetic nephropathy and fibrillary glomerulonephritis can be easily distinguished from anti-GBM disease on both clinical and histopathologic grounds. Circulating anti-GBM antibodies are absent in both disorders, and crescents are not seen in diabetic nephropathy. The history of diabetes, the finding of diabetic glomerulosclerosis on light microscopy, and, in fibrillary glomerulonephritis, the presence of the characteristic fibrils on electron microscopy are also helpful.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3188385049">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Anti-GBM antibody disease is a disorder in which circulating antibodies are directed against an antigen intrinsic to the glomerular basement membrane (GBM) in the kidney, thereby resulting in acute or rapidly progressive glomerulonephritis that is typically associated with crescent formation. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The principal target for the anti-GBM antibodies is the NC1 domain of the alpha-3 chain of type IV collagen (alpha-3(IV) chain), which is highly expressed in the GBM and alveoli. Anti-GBM disease is most often idiopathic, although it can occasionally follow pulmonary injury or kidney injury, such as infections, inhalation of hydrocarbons, or other forms of glomerulonephritis. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Most (&gt;90 percent) patients with anti-GBM disease present with clinical features of rapidly progressive glomerulonephritis. Somewhere between 20 to 60 percent present with concomitant alveolar hemorrhage, and a small proportion of patients present with isolated pulmonary findings. Systemic complaints and signs, such as malaise, weight loss, fever, or arthralgia, are usually present only during a short prodromal period. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect anti-GBM disease
         </strong>
         – The diagnosis of anti-GBM disease should be suspected in any patient presenting with clinical symptoms and/or signs concerning for acute glomerulonephritis (eg, hematuria, proteinuria, cellular casts, kidney function impairment), particularly if accompanied by rapid progression and/or pulmonary (alveolar) hemorrhage. Anti-GBM disease should also be suspected in patients presenting with alveolar hemorrhage alone since pulmonary disease may be the predominant presenting feature in rare cases. (See
         <a class="local">
          'When to suspect anti-GBM disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, the following clinical scenarios should raise suspicion for a less common variant of anti-GBM disease:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with features of systemic disease, such as malaise, weight loss, fever, or arthralgia, which suggest a concurrent vasculitis (see
         <a class="local">
          'Double-positive anti-GBM and ANCA-associated disease'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a known diagnosis of membranous nephropathy (MN) who develop a rapid decline in kidney function (see
         <a class="local">
          'Anti-GBM disease associated with membranous nephropathy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with proteinuria, hematuria, or mild kidney function impairment who have linear immunoglobulin G (IgG) staining of the GBM on kidney biopsy (see
         <a class="local">
          'Anti-GBM disease without detectable circulating anti-GBM antibodies'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney transplant recipients with underlying Alport syndrome (hereditary nephritis) who present with acute glomerulonephritis or graft failure (see
         <a class="local">
          'Anti-GBM disease after transplantation'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establishing the diagnosis
         </strong>
         – The diagnosis of anti-GBM disease requires demonstration of anti-GBM antibodies either in the serum or the kidney. Kidney biopsy should be performed, unless there is a contraindication, because the accuracy of serologic assays is variable. In addition, kidney biopsy provides important information regarding the activity and chronicity of kidney involvement that may help guide therapy and excludes other possible causes of glomerulonephritis. Testing for antineutrophil cytoplasmic antibodies (ANCA) should be performed in all patients who are diagnosed with anti-GBM disease. The presence of both anti-GBM antibodies and ANCA supports a diagnosis of double-positive anti-GBM and ANCA-associated disease. (See
         <a class="local">
          'Establishing the diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2821993494">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Raghu Kalluri, MD, PhD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol 2017; 12:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canney M, O'Hara PV, McEvoy CM, et al. Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol 2016; 11:1392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor DM, Yehia M, Simpson IJ, et al. Anti-glomerular basement membrane disease in Auckland. Intern Med J 2012; 42:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutgers A, Slot M, van Paassen P, et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005; 46:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirayama K, Yamagata K, Kobayashi M, Koyama A. Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol 2008; 12:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li FK, Tse KC, Lam MF, et al. Incidence and outcome of antiglomerular basement membrane disease in Chinese. Nephrology (Carlton) 2004; 9:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int 2003; 63:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang W, McDonald SP, Hawley CM, et al. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int 2013; 83:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolton WK. Goodpasture's syndrome. Kidney Int 1996; 50:1753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage CO, Pusey CD, Bowman C, et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986; 292:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer EG, Lager DJ. Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. Am J Clin Pathol 2006; 125:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segelmark M, Hellmark T, Wieslander J. The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin Pract 2003; 94:c59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorval G, Lion M, Guérin S, et al. Immunoadsorption in Anti-GBM Glomerulonephritis: Case Report in a Child and Literature Review. Pediatrics 2017; 140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalluri R, Wilson CB, Weber M, et al. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol 1995; 6:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pokidysheva EN, Seeger H, Pedchenko V, et al. Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture's and Alport diseases. J Biol Chem 2021; 296:100590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalluri R, Sun MJ, Hudson BG, Neilson EG. The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen. J Biol Chem 1996; 271:9062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merkel F, Kalluri R, Marx M, et al. Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NC1 domain on alpha 3 type IV collagen. Kidney Int 1996; 49:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leinonen A, Netzer KO, Boutaud A, et al. Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain. Kidney Int 1999; 55:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Derry CJ, Pusey CD. Tissue-specific distribution of the Goodpasture antigen demonstrated by 2-D electrophoresis and western blotting. Nephrol Dial Transplant 1994; 9:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Cui Z, Yang R, et al. Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int 2009; 76:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010; 363:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCall AS, Bhave G, Pedchenko V, et al. Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes. J Am Soc Nephrol 2018; 29:2619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao J, Yan Y, Cui Z, et al. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity. Hum Immunol 2009; 70:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segelmark M, Butkowski R, Wieslander J. Antigen restriction and IgG subclasses among anti-GBM autoantibodies. Nephrol Dial Transplant 1990; 5:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moulis G, Huart A, Guitard J, et al. IgA-mediated anti-glomerular basement membrane disease: an uncommon mechanism of Goodpasture's syndrome. Clin Kidney J 2012; 5:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohlsson S, Herlitz H, Lundberg S, et al. Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease. Am J Kidney Dis 2014; 63:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang XF, Kuang H, Shen CR, et al. The Prevalence and Characteristics of Circulating IgA Anti-Glomerular Basement Membrane Autoantibodies in Anti-Glomerular Basement Membrane Disease. Kidney Int Rep 2023; 8:2395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borza DB, Chedid MF, Colon S, et al. Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis 2005; 45:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peña C, Valjalo R, Rocca X, et al. Anti-glomerular basement membrane disease due to monoclonal IgG Lambda antibodies: a very rare case of monoclonal gammopathy of renal significance. Ann Hematol 2019; 98:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson SW, Arbogast CB, Baker TP, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 2011; 22:1946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutgers A, Meyers KE, Canziani G, et al. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen. Kidney Int 2000; 58:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cui Z, Wang HY, Zhao MH. Natural autoantibodies against glomerular basement membrane exist in normal human sera. Kidney Int 2006; 69:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyce NW, Holdsworth SR. Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage. Am J Kidney Dis 1986; 8:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 1983; 2:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Rostan y Pérez GM, García Bragado F, Puras Gil AM. Pulmonary hemorrhage and antiglomerular basement membrane antibody-mediated glomerulonephritis after exposure to smoked cocaine (crack): a case report and review of the literature. Pathol Int 1997; 47:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen CR, Jia XY, Luo W, et al. Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease. J Am Soc Nephrol 2021; 32:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang A, Zhao X, Tao T, et al. Unleashing the power of complement activation: unraveling renal damage in human anti-glomerular basement membrane disease. Front Immunol 2023; 14:1229806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otten MA, Groeneveld TW, Flierman R, et al. Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice. J Immunol 2009; 183:3980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caillard P, Vigneau C, Halimi JM, et al. Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease. Front Immunol 2023; 14:1190394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu M, Wang J, Le W, et al. Relationship Between Serum Complement C3 Levels and Outcomes Among Patients With Anti-GBM Disease. Front Immunol 2022; 13:929155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma R, Cui Z, Liao YH, Zhao MH. Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease. J Clin Immunol 2013; 33:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds J, Norgan VA, Bhambra U, et al. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J Am Soc Nephrol 2002; 13:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salama AD, Chaudhry AN, Holthaus KA, et al. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int 2003; 64:1685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds J, Khan SB, Allen AR, et al. Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. Kidney Int 2004; 66:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean EG, Wilson GR, Li M, et al. Experimental autoimmune Goodpasture's disease: a pathogenetic role for both effector cells and antibody in injury. Kidney Int 2005; 67:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf D, Hochegger K, Wolf AM, et al. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol 2005; 16:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salama AD, Chaudhry AN, Ryan JJ, et al. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J Am Soc Nephrol 2001; 12:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hünemörder S, Treder J, Ahrens S, et al. TH1 and TH17 cells promote crescent formation in experimental autoimmune glomerulonephritis. J Pathol 2015; 237:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu J, Borillo J, Glass WF, et al. T-cell epitope of alpha3 chain of type IV collagen induces severe glomerulonephritis. Kidney Int 2003; 64:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robertson J, Wu J, Arends J, et al. Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis. Kidney Int 2005; 68:1061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds J, Abbott DS, Karegli J, et al. Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis. Am J Pathol 2009; 174:2202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arends J, Wu J, Borillo J, et al. T cell epitope mimicry in antiglomerular basement membrane disease. J Immunol 2006; 176:1252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu J, Arends J, Borillo J, et al. A self T cell epitope induces autoantibody response: mechanism for production of antibodies to diverse glomerular basement membrane antigens. J Immunol 2004; 172:4567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds J, Preston GA, Pressler BM, et al. Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'. J Autoimmun 2015; 59:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen L, Hellmark T, Pedchenko V, et al. A nephritogenic peptide induces intermolecular epitope spreading on collagen IV in experimental autoimmune glomerulonephritis. J Am Soc Nephrol 2006; 17:3076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zou J, Hannier S, Cairns LS, et al. Healthy individuals have Goodpasture autoantigen-reactive T cells. J Am Soc Nephrol 2008; 19:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pusey CD. Anti-glomerular basement membrane disease. Kidney Int 2003; 64:1535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prendecki M, Clarke C, Cairns T, et al. Anti-glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int 2020; 98:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med 2008; 359:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi N, Tsuji K, Tamiya H, et al. Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report. Lung Cancer 2018; 122:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hultin S, Nahar K, Menzies AM, et al. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrol 2020; 21:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyriazis P, Tiwary A, Freeman J, et al. Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report. J Med Case Rep 2021; 15:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Javaugue V, Watson MJ, Fervenza FC, Nasr SH. Atypical Antiglomerular Basement Membrane Nephritis Following Immune Checkpoint Inhibitor. Kidney Int Rep 2022; 7:1913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angioi A, Cheungpasitporn W, Sethi S, et al. Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings . Clin Nephrol 2017; 88:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Apice AJ, Kincaid-Smith P, Becker GH, et al. Goodpasture's syndrome in identical twins. Ann Intern Med 1978; 88:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonsen H, Brun C, Thomsen OF, et al. Goodpasture's syndrome in twins. Acta Med Scand 1982; 212:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999; 56:1638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang R, Cui Z, Zhao J, Zhao MH. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin Immunol 2009; 133:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitagawa W, Imai H, Komatsuda A, et al. The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant 2008; 23:3126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalluri R, Danoff TM, Okada H, Neilson EG. Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest 1997; 100:2263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behmoaras J, Bhangal G, Smith J, et al. Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility. Nat Genet 2008; 40:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behmoaras J, Smith J, D'Souza Z, et al. Genetic loci modulate macrophage activity and glomerular damage in experimental glomerulonephritis. J Am Soc Nephrol 2010; 21:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher M, Pusey CD, Vaughan RW, Rees AJ. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int 1997; 51:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ooi JD, Chang J, O'Sullivan KM, et al. The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN. J Am Soc Nephrol 2013; 24:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ooi JD, Petersen J, Tan YH, et al. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 2017; 545:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huynh M, Eggenhuizen PJ, Olson GL, et al. HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen. J Autoimmun 2019; 103:102276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol 1999; 10:2446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ang C, Savige J, Dawborn J, et al. Anti-glomerular basement membrane (GBM)-antibody-mediated disease with normal renal function. Nephrol Dial Transplant 1998; 13:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazor R, Bigay-Gamé L, Cottin V, et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore) 2007; 86:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalluri R, Meyers K, Mogyorosi A, et al. Goodpasture syndrome involving overlap with Wegener's granulomatosis and anti-glomerular basement membrane disease. J Am Soc Nephrol 1997; 8:1795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 2017; 92:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hellmark T, Niles JL, Collins AB, et al. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 1997; 8:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang R, Hellmark T, Zhao J, et al. Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2007; 18:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clerte M, Philip R, Levi C, et al. Renal and overall outcomes of double-positive (ANCA and anti-GBM antibodies) patients compared to ANCA-associated vasculitis patients with severe renal involvement: A multicenter retrospective study with systematic renal pathology analysis. Scand J Rheumatol 2022; 51:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sano T, Kamata K, Shigematsu H, Kobayashi Y. A case of anti-glomerular basement membrane glomerulonephritis superimposed on membranous nephropathy. Nephrol Dial Transplant 2000; 15:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basford AW, Lewis J, Dwyer JP, Fogo AB. Membranous nephropathy with crescents. J Am Soc Nephrol 2011; 22:1804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jia XY, Hu SY, Chen JL, et al. The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy. Kidney Int 2014; 85:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nikolopoulou A, Huang-Doran I, McAdoo SP, et al. Membranous Glomerulonephritis With Crescents. Kidney Int Rep 2019; 4:1577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bu L, Said SM, Herrera Hernandez L, et al. The Characteristics of Concurrent Anti-Glomerular Basement Membrane Nephritis and Membranous Nephropathy. Kidney Int Rep 2023; 8:2164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad SB, Santoriello D, Canetta P, et al. Concurrent Anti-Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. Am J Kidney Dis 2021; 78:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int 2016; 89:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen CR, Jia XY, Cui Z, et al. Clinical-Pathological Features and Outcome of Atypical Anti-glomerular Basement Membrane Disease in a Large Single Cohort. Front Immunol 2020; 11:2035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuang H, Shen CR, Jia XY, et al. Autoantibodies against laminin-521 are pathogenic in anti-glomerular basement membrane disease. Kidney Int 2023; 104:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salama AD, Dougan T, Levy JB, et al. Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 2002; 39:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clavarino G, Gauthier A, Hellmark T, et al. Routinely used immunoassays do not detect circulating anti-GBM antibodies against native NC1 hexamer and EA epitope of the α3 chain of type IV collagen. Eur J Immunol 2018; 48:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cui Z, Zhao MH, Singh AK, Wang HY. Antiglomerular basement membrane disease with normal renal function. Kidney Int 2007; 72:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi S, Lewin M, Lopez L, Lager D. Linear anti-glomerular basement membrane IgG but no glomerular disease: Goodpasture's syndrome restricted to the lung. Nephrol Dial Transplant 2007; 22:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalluri R, Weber M, Netzer KO, et al. COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1994; 45:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andres G, Brentjens J, Kohli R, et al. Histology of human tubulo-interstitial nephritis associated with antibodies to renal basement membranes. Kidney Int 1978; 13:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalluri R, Petrides S, Wilson CB, et al. Anti-alpha1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Ann Intern Med 1996; 124:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litwin CM, Mouritsen CL, Wilfahrt PA, et al. Anti-glomerular basement membrane disease: role of enzyme-linked immunosorbent assays in diagnosis. Biochem Mol Med 1996; 59:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinico RA, Radice A, Corace C, et al. Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays. Nephrol Dial Transplant 2006; 21:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Browne G, Brown PA, Tomson CR, et al. Retransplantation in Alport post-transplant anti-GBM disease. Kidney Int 2004; 65:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charytan D, MacDonald B, Sugimoto H, et al. An unusual case of pulmonary-renal syndrome associated with defects in type IV collagen composition and anti-glomerular basement membrane autoantibodies. Am J Kidney Dis 2005; 45:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West SC, Arulkumaran N, Ind PW, Pusey CD. Pulmonary-renal syndrome: a life threatening but treatable condition. Postgrad Med J 2013; 89:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns AP, Fisher M, Li P, et al. Molecular analysis of HLA class II genes in Goodpasture's disease. QJM 1995; 88:93.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3108 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28515156" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Anti-Glomerular Basement Membrane Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27401523" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22032242" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Anti-glomerular basement membrane disease in Auckland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16112043" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18392773" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15056270" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Incidence and outcome of antiglomerular basement membrane disease in Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12631105" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Rapidly progressive crescentic glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23254902" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8914046" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Goodpasture's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3080145" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16613350" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12902632" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29054981" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Immunoadsorption in Anti-GBM Glomerulonephritis: Case Report in a Child and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11388816" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8589284" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12815141" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33774048" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Collagen IVα345 dysfunction in glomerular basement membrane diseases. I. Discovery of a COL4A3 variant in familial Goodpasture's and Alport diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8621555" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8691734" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NC1 domain on alpha 3 type IV collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027929" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8084446" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Tissue-specific distribution of the Goodpasture antigen demonstrated by 2-D electrophoresis and western blotting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19741587" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660402" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30279272" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19364515" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2128958" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Antigen restriction and IgG subclasses among anti-GBM autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26069798" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : IgA-mediated anti-glomerular basement membrane disease: an uncommon mechanism of Goodpasture's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24189476" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Circulating anti-glomerular basement membrane antibodies with predominance of subclass IgG4 and false-negative immunoassay test results in anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38025241" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The Prevalence and Characteristics of Circulating IgA Anti-Glomerular Basement Membrane Autoantibodies in Anti-Glomerular Basement Membrane Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15685519" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30302532" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Anti-glomerular basement membrane disease due to monoclonal IgG Lambda antibodies: a very rare case of monoclonal gammopathy of renal significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21868497" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10886555" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16518348" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Natural autoantibodies against glomerular basement membrane exist in normal human sera.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3728460" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6140495" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9361103" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pulmonary hemorrhage and antiglomerular basement membrane antibody-mediated glomerulonephritis after exposure to smoked cocaine (crack): a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33893224" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37781380" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Unleashing the power of complement activation: unraveling renal damage in human anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19710463" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Both complement and IgG fc receptors are required for development of attenuated antiglomerular basement membrane nephritis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37475859" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35874697" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Relationship Between Serum Complement C3 Levels and Outcomes Among Patients With Anti-GBM Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22941511" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Complement activation contributes to the injury and outcome of kidney in human anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11805163" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14531801" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15458437" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15673304" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Experimental autoimmune Goodpasture's disease: a pathogenetic role for both effector cells and antibody in injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15788479" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518784" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25965582" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : TH1 and TH17 cells promote crescent formation in experimental autoimmune glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12969147" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : T-cell epitope of alpha3 chain of type IV collagen induces severe glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16105036" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19406992" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16394016" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : T cell epitope mimicry in antiglomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15034074" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A self T cell epitope induces autoantibody response: mechanism for production of antibodies to diverse glomerular basement membrane antigens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25841937" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17005930" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A nephritogenic peptide induces intermolecular epitope spreading on collagen IV in experimental autoimmune glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18216317" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Healthy individuals have Goodpasture autoantigen-reactive T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12969182" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32599088" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Anti-glomerular basement membrane disease during the COVID-19 pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18703487" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Anti-glomerular basement membrane disease after alemtuzumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30032835" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Goodpasture's disease in a patient with advanced lung cancer treated with nivolumab: An autopsy case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32894101" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33810799" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35967108" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Atypical Antiglomerular Basement Membrane Nephritis Following Immune Checkpoint Inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28853702" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings .
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/563692" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Goodpasture's syndrome in identical twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7158437" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Goodpasture's syndrome in twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10571772" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19654074" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18413431" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9410904" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16482158" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18443593" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20488952" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Genetic loci modulate macrophage activity and glomerular damage in experimental glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8995737" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23411782" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28467828" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31104947" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10541306" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9568853" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Anti-glomerular basement membrane (GBM)-antibody-mediated disease with normal renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17505257" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9355084" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Goodpasture syndrome involving overlap with Wegener's granulomatosis and anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15458448" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Clinical features and outcome of patients with both ANCA and anti-GBM antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28506760" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9071706" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparison of anti-GBM antibodies in sera with or without ANCA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17329569" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34169779" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Renal and overall outcomes of double-positive (ANCA and anti-GBM antibodies) patients compared to ANCA-associated vasculitis patients with severe renal involvement: A multicenter retrospective study with systematic renal pathology analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10910453" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A case of anti-glomerular basement membrane glomerulonephritis superimposed on membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21903992" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Membranous nephropathy with crescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24048374" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31890999" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Membranous Glomerulonephritis With Crescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37850023" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The Characteristics of Concurrent Anti-Glomerular Basement Membrane Nephritis and Membranous Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33421452" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Concurrent Anti-Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26994577" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33013861" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Clinical-Pathological Features and Outcome of Atypical Anti-glomerular Basement Membrane Disease in a Large Single Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37598856" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Autoantibodies against laminin-521 are pathogenic in anti-glomerular basement membrane disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12046026" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29644627" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Routinely used immunoassays do not detect circulating anti-GBM antibodies against native NC1 hexamer and EA epitope of theα3 chain of type IV collagen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17851468" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Antiglomerular basement membrane disease with normal renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17277338" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Linear anti-glomerular basement membrane IgG but no glomerular disease: Goodpasture's syndrome restricted to the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8196274" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/362036" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Histology of human tubulo-interstitial nephritis associated with antibodies to renal basement membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8607593" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Anti-alpha1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8902194" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Anti-glomerular basement membrane disease: role of enzyme-linked immunosorbent assays in diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16234289" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14717941" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Retransplantation in Alport post-transplant anti-GBM disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806477" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : An unusual case of pulmonary-renal syndrome associated with defects in type IV collagen composition and anti-glomerular basement membrane autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23349383" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Pulmonary-renal syndrome: a life threatening but treatable condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7704568" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Molecular analysis of HLA class II genes in Goodpasture's disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
